Seaport Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a pipeline of transformative medicines for neuropsychiatric disorders. The company utilizes its proprietary Glyph platform, a specialized drug-delivery technology designed to leverage the body’s natural lymphatic transport system. This approach allows for the oral administration of therapeutics that would otherwise be limited by poor absorption or significant first-pass metabolism in the liver, potentially reducing side effects and enhancing therapeutic reach to the brain. Seaport’s clinical pipeline is focused on addressing significant unmet needs in mental health. Its lead candidates include SPT-300, an oral prodrug of allopregnanolone being developed for the treatment of major depressive disorder (MDD) with postpartum depression; SPT-320, an oral prodrug of agomelatine intended for generalized anxiety disorder (GAD); and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen being developed for various neuropsychiatric conditions. Founded by PureTech Health and led by an experienced management team with a track record in CNS drug development, Seaport Therapeutics aims to redefine the treatment landscape for depression, anxiety, and other neurological conditions by optimizing the pharmacological profiles of proven molecules through innovative lymphatic targeting.
No data found.